Y. Alamanos and A. Drosos, Epidemiology of adult rheumatoid arthritis, Autoimmunity Reviews, vol.4, issue.3, pp.130-166, 2005.
DOI : 10.1016/j.autrev.2004.09.002

T. Uhlig and T. Kvien, Is rheumatoid arthritis disappearing?, Annals of the Rheumatic Diseases, vol.64, issue.1, pp.7-10, 2005.
DOI : 10.1136/ard.2004.023044

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1755215

L. Garrec, M. Bouvet, M. Koubi, and M. , Comptes nationaux de la santé ? 2011. DREES (Direction de la recherche, des e ´tudes, de l'e ´valuation et des statistiques) Available, 2012.

F. Guillemin, S. Durieux, J. Daurès, A. Lafuma, and A. Saraux, Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists, J Rheumatol, vol.31, pp.1297-304, 2004.

G. Kobelt, A. Woronoff, B. Richard, P. Peeters, and J. Sany, Disease status, costs and quality of life of patients with rheumatoid arthritis in France: The ECO-PR Study, Joint Bone Spine, vol.75, issue.4, pp.408-423, 2008.
DOI : 10.1016/j.jbspin.2007.07.015

F. Wolfe and K. Michaud, The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study, Arthritis Research & Therapy, vol.12, issue.2, p.35, 2010.
DOI : 10.1186/ar2944

J. Lundkvist, F. Kastang, and G. Kobelt, The burden of rheumatoid arthritis and access to treatment: health burden and costs, The European Journal of Health Economics, vol.13, issue.Suppl, pp.49-60, 2008.
DOI : 10.1007/s10198-007-0088-8

B. Fautrel, S. Verstappen, and A. Boonen, Economic consequences and potential benefits, Best Practice & Research Clinical Rheumatology, vol.25, issue.4, pp.607-631, 2011.
DOI : 10.1016/j.berh.2011.10.001

H. Rosery, R. Bergemann, and S. Maxion-bergemann, International Variation in Resource Utilisation and Treatment Costs for Rheumatoid Arthritis, PharmacoEconomics, vol.2, issue.1, pp.243-57, 2005.
DOI : 10.2165/00019053-200523030-00005

K. Saag, G. Teng, N. Patkar, J. Anuntiyo, and C. Finney, American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis, Arthritis & Rheumatism, vol.21, issue.2, pp.762-84, 2008.
DOI : 10.1002/art.23721

A. Finckh, N. Bansback, C. Marra, A. Anis, and K. Michaud, Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents, Annals of Internal Medicine, vol.151, issue.9, pp.612-633, 2009.
DOI : 10.7326/0003-4819-151-9-200911030-00006

M. Benucci, G. Saviola, M. Manfredi, P. Sarzi-puttini, and F. Atzeni, Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature, International Journal of Rheumatology, vol.28, issue.5, supplement 61, pp.10-1155, 2011.
DOI : 10.1093/rheumatology/ker084

L. Franke, A. Ament, M. Van-de-laar, A. Boonen, and J. Severens, Cost-ofillness of rheumatoid arthritis and ankylosing spondylitis, Clin Exp Rheumatol, vol.27, pp.118-141, 2009.

B. Combe, J. Benessiano, F. Brenbaum, A. Cantagrel, and J. Daurès, The ESPOIR cohort: A ten-year follow-up of early arthritis in France, Joint Bone Spine, vol.74, issue.5, pp.440-445, 2007.
DOI : 10.1016/j.jbspin.2007.06.001

V. Bories-maskulova, Démographie et honoraires des médecins libéraux en Caisse nationale de l'Assurance Maladie 23 Available: http://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/points- de-repere/n-23-demographie-honoraires-des-medecins-2006, 2006.

K. Chevreul, A. Prigent, A. Bourmaud, M. Leboyer, and I. Durand-zaleski, The cost of mental disorders in France, European Neuropsychopharmacology, vol.23, issue.8, 2012.
DOI : 10.1016/j.euroneuro.2012.08.012

M. Coldefy, L. Com-ruelle, V. Lucas-gabrielli, and L. Marcoux, Les distances d'accès aux soins en France métropolitaine au 1er janvier Available: http://www.irdes.fr/ Publications, IRDES, 2007.

. Agence-technique-de, ENCC MCO 2006: National cost care for medecin surgery obstretics sector (acute care sector), database on the Internet] Available, 2006.

R. Grieve, R. Nixon, S. Thompson, and N. C. , Using multilevel models for assessing the variability of multinational resource use and cost data, Health Economics, vol.11, issue.2, pp.185-96, 2005.
DOI : 10.1002/hec.916

S. Raudenbush and A. Bryk, Hierarchical Linear Models: Applications and Data Analysis Methods. Second Edition, 2001.

J. Fries, P. Spitz, R. Kraines, and H. Holman, Measurement of patient outcome in arthritis, Arthritis & Rheumatism, vol.33, issue.2, pp.137-182, 1980.
DOI : 10.1002/art.1780230202

J. Smolen, R. Landewé, F. Breedveld, M. Dougados, and P. Emery, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Annals of the Rheumatic Diseases, vol.69, issue.6, pp.964-75, 2010.
DOI : 10.1136/ard.2009.126532

P. Allison, Imputation of Categorical Variables with PROC MI, Proceedings of the Thirtieth Annual SAS Users Group International (SUGI) Conference, 2005.

J. Graham, Missing Data Analysis: Making It Work in the Real World, Annual Review of Psychology, vol.60, issue.1, pp.549-76, 2009.
DOI : 10.1146/annurev.psych.58.110405.085530

L. Collins, J. Schafer, and C. Kam, A comparison of inclusive and restrictive strategies in modern missing data procedures., Psychological Methods, vol.6, issue.4, pp.330-51, 2001.
DOI : 10.1037/1082-989X.6.4.330

D. Rubin, Multiple Imputation for Nonresponse in Surveys, 1987.
DOI : 10.1002/9780470316696

B. Fautrel, B. Combe, N. Rincheval, M. Dougados, and . Espoir-scientific-commitee, Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data, Annals of the Rheumatic Diseases, vol.71, issue.3, pp.386-89, 2012.
DOI : 10.1136/annrheumdis-2011-200259

URL : https://hal.archives-ouvertes.fr/hal-00790235

S. Adami, D. Bernardi, E. Rossi, M. Rossini, D. Rosa et al., Drug use and Cost Evaluation In Rheumatoid Arthritis Patients. Value Health16, p.221, 2013.

A. Kawatkar, S. Jacobsen, G. Levy, S. Medhekar, and K. Venkatasubramaniam, Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey, Arthritis Care & Research, vol.23, issue.11, pp.1649-56, 2012.
DOI : 10.1002/acr.21755

B. Fautrel, S. Verstappen, and A. Boonen, Economic consequences and potential benefits, Best Practice & Research Clinical Rheumatology, vol.25, issue.4, pp.607-631, 2011.
DOI : 10.1016/j.berh.2011.10.001

E. Hallert, M. Husberg, and T. Skogh, 28-joint count disease activity score at 3 months after diagnosis of early rheumatoid arthritis is strongly associated with direct and indirect costs over the following 4 years: the Swedish TIRA project, Rheumatology, vol.50, issue.7, pp.1259-67, 2011.
DOI : 10.1093/rheumatology/keq444

K. Michaud, J. Messer, H. Choi, and F. Wolf, Direct medical costs and their predictors in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.38, issue.Suppl 9, pp.2750-62, 2003.
DOI : 10.1002/art.11439

T. Zhu, L. Tam, and E. Li, Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study, Rheumatology, vol.50, issue.7, pp.1293-1301, 2011.
DOI : 10.1093/rheumatology/ker014

B. Combe, R. Landewe, C. Lukas, H. Bolosiu, and F. Breedveld, EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT), Annals of the Rheumatic Diseases, vol.66, issue.1, pp.34-45, 2007.
DOI : 10.1136/ard.2005.044354

R. Knevel, M. Schoels, T. Huizinga, D. Aletaha, and G. Burmester, Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.69, issue.6, pp.987-994, 2010.
DOI : 10.1136/ard.2009.126748

D. Rubin and A. Baddeley, Telescoping is not time compression: A model, Memory & Cognition, vol.2, issue.No. 291, pp.653-61, 1989.
DOI : 10.3758/BF03202626

J. Schafer and J. Graham, Missing data: Our view of the state of the art., Psychological Methods, vol.7, issue.2, pp.147-77, 2002.
DOI : 10.1037/1082-989X.7.2.147

P. Hippel, Should a Normal Imputation Model be Modified to Impute Skewed Variables?, Sociological Methods & Research, vol.39, issue.1, pp.105-143, 2013.
DOI : 10.1037/1082-989X.7.2.147

A. Finckh, N. Bansback, M. Liang, and M. Boers, Cost-Effectiveness of Biologics in Early Rheumatoid Arthritis, Annals of Internal Medicine, vol.152, issue.5, pp.333-337, 2010.
DOI : 10.7326/0003-4819-152-5-201003020-00018